Why the study?
Do antiplatelet agents decrease the risk of vascular events?
Do antiplatelet agents decrease the risk of vascular events?
This review highlights the efficacy of antiplatelet agents in preventing vascular events while noting the critical need for reliable markers of platelet activity to identify high-risk patients.
Answers are grounded in this paper and cite their sources.
Supports antiplatelet use for vascular prevention; leaves open validation of reliable platelet activity markers for risk stratification.
Epidemiological studies have linked platelet hyperactivity with an increased risk of vascular events. Even more convincing is the evidence from appropriately designed clinical trials showing that antiplatelet agents decrease the risk of vascular events (e.g. myocardial infarction, MI and stroke). These findings are compatible with the known thrombotic action of platelets. A considerable limitation in platelet research is the absence of a reliable, universally accepted marker of platelet activity. Therefore, it is difficult to reliably identify the 'high risk patient' and/or evaluate the efficacy of any administered treatment other than by calculating event rates over a period of time. This review will focus on the preventive aspects of antiplatelet intervention while also briefly considering the assessment of platelet hyperactivity and the mechanisms involved in platelet-induced thrombosis.
No takes yet. Share an insight, caveat, or question.
Jagroop et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: